Journal of Traditional Chinese Medicine ›› 2022, Vol. 42 ›› Issue (4): 493-504.DOI: 10.19852/j.cnki.jtcm.20220617.001
• Systematic Reviews • Previous Articles Next Articles
Efficacy and safety of external application of Chinese herbal medicine for psoriasis vulgaris: a systematic review of randomized controlled trials
LIN Yi1, LI Xun2, WANG Zi1, ZHENG Xiaoran1, HANG Haiyan1, LI Lingling1(
)
- 1 Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
2 Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
-
Received:2021-07-21Accepted:2021-10-09Online:2022-08-15Published:2022-07-12 -
Contact:LI Lingling -
About author:LI Lingling, Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China. abcling3238@sina.com, Telephone: +86-13661124312
-
Supported by:Study the Immunoanti-inflammatory Mechanism of Cooling Blood Detoxification Methods for Psoriasis Treatment from Influence of S1P/S1PRs to Th17/KC Inflammatory Axis(81874393)
Cite this article
LIN Yi, LI Xun, WANG Zi, ZHENG Xiaoran, HANG Haiyan, LI Lingling. Efficacy and safety of external application of Chinese herbal medicine for psoriasis vulgaris: a systematic review of randomized controlled trials[J]. Journal of Traditional Chinese Medicine, 2022, 42(4): 493-504.
share this article
Figure 1 Flowchart depicting the study selection CNKI: China National Knowledge Infrastructure Database; VIP: China Science and Technology Journal Database; RCT: randomized controlled trial.
Figure 1 Flowchart depicting the study selection CNKI: China National Knowledge Infrastructure Database; VIP: China Science and Technology Journal Database; RCT: randomized controlled trial.
Figure 2 Risk of bias summary
Figure 2 Risk of bias summary
Table 1 Characteristics of the 19 included studies comparing ex-CHM with other therapies for psoriasis vulgaris
| Author, year | Disease stage | Diagnostic criteria | Sample size E/C | Age E/C (years) | Duration E/C (years) | Intervention E/C | Treatment cycle (weeks) | follow-up (months) | Outcome measures |
|---|---|---|---|---|---|---|---|---|---|
| Cui et al, 2008 | Quiescent stage | China clinical dermatology | 62/57 | 45.82±13.89/ 38.72±12.17 | 160.92±147.24 /129.56±106.51 months | CHM bath+NB-UVB/ NB-UVB | 8 | NA | ①②⑤ |
| Zhang et al, 2009 | Quiescent stage | China clinical dermatology | 68/72 | 28.1±10.3/ 29.7±11.4 | 6.2±5.1 /5.8±4.8 | CHM fumigation+NB-UVB/ NB-UVB | 4 | NA | ①⑤ |
| Wu et al, 2010 | NA | Dermatology and venereology | 40/39 | 36.45±8.52/ 36.67±8.36 | 7.86±2.41 /8.06±2.65 | CHM bath+NB-UVB+/ NB-UVB | 12 | NA | ①②⑤ |
| Zhang and Wei, 2010 | Quiescent stage | China clinical dermatology | 30/30 | 36.5/34.6 | 10.37±9.59/ 10.85±10.46 | CHM bath+NB-UVB/ NB-UVB | 8 | NA | ①②⑤ |
| Shi et al, 2011 | Quiescent stage | Yang guoliang dermatology | 170/168 | 20-62/22-61 | 12.9/13.5 | CHM bath+NB-UVB/ NB-UVB | 8 | 6 | ①③⑤ |
| Wang et al, 2011 | NA | Modern Dermatology and venereology | 50/50 | 38.2/37.5 | 8.6/7.8 | CHM bath+NB-UVB+urea ointment/NB-UVB+urea ointment | 4 | NA | ①⑤ |
| Wu et al, 2011 | NA | Standards for diagnosis and curative effect of Chinese medical symptom | 75/65 | 32.5/34.8 | 18/20 months | CHM bath+NB-UVB+ex-hormone/ NB-UVB+ex-hormone | 6 | NA | ①②⑤ |
| Zhang et al, 2011 | NA | Guiding principles for clinical research of new Chinese medicine | 40/42 | 33.8±4.7/ 27.1±5.4 | 3.9±1.6/ 4.3±2.8 | CHM fumigation+NB-UVB/ NB-UVB | 4 | NA | ①②⑤ |
| Li et al, 2012 | NA | China clinical dermatology | 30/30 | 39.90±11.75/ 37.33±11.13 | 8.58±6.33/ 8.11±6.64 | CHM bath+NB-UVB+ex-hormone/ NB-UVB+ex-hormone | 4 | NA | ①②④⑤ |
| Luo et al, 2014 | Quiescent stage | China clinical dermatology | 56/52 | 31.52±6.23 | 3.5 months-13 years | CHM bath+NB-UVB/ NB-UVB | 4 | 6 | ①③⑤ |
| Su et al, 2015 | NA | China clinical dermatology | 42/43 | 38.25±8.33/ 42.57±11.79 | 13.57±6.85/ 15.89±7.23 | CHM bath+308nm excimer laser/ 308nm excimer laser | 8 | NA | ①②④⑤ |
| Wei and Jiang, 2015 | NA | China clinical dermatology | 64/64 | 14-75/17-68 | 1 month-25 years/ 6 months-20 years | CHM fumigation combined with external washing+acitretin/acitretin | 8 | NA | ①②⑤ |
| Zhang, 2015 | NA | Guiding principles for clinical research of new Chinese medicine | 29/29 | 44.21±11.97/ 41.97±10.46 | 9.62±9.01/ 7.52±6.08 | CHM ointment/tretinoin cream | 4 | NA | ①②⑤ |
| Chen, 2016 | NA | China clinical dermatology | 60/60 | 41.5/40.5 | 8.9/9.1 | CHM ointment+acitretin/acitretin | 12 | NA | ①⑤ |
| Fan, 2016 | NA | China clinical dermatology | 30/30 | 41.3±9.96/41.0±10.73 | 7.37±4.55/6.37±4.42 | CHM bath+NB-UVB/NB-UVB | 4 | NA | ①②④⑤ |
| Jiang, 2017 | Quiescent stage | China clinical dermatology | 30/30 | 43.23±10.70/ 42.43±11.29 | 1.85±0.89/ 1.78±0.81 | CHM external washing+calcipotriol ointment/calcipotriol ointment | 8 | NA | ①②⑤ |
| Song et al, 2017 | Quiescent stage | China clinical dermatology | 42/42 | 49.6±7.8/ 51.2±8.5 | 8.4±5.2/ 7.7±5.9 | CHM bath+NB-UVB+urea ointment/NB-UVB+urea ointment | 8 | NA | ①②④⑤ |
| Wang and Lu, 2019 | Quiescent stage | Clinical guidelines: venereal diseases | 46/41 | 41.59±10.83/ 42.24±9.66 | 6.20±2.72/ 6.46±2.53 | CHM external washing/ calcipotriol ointment | 6 | NA | ①②⑤ |
| Lin et al, 2020 | NA | Modern Dermatology | 40/40 | 39.43±9.35/ 42.47±9.08 | 32.55±5.98/ 32.56±5.72 months | CHM fumigation+calcipotriol ointment/calcipotriol ointment | 4 | NA | ①②⑤ |
Table 1 Characteristics of the 19 included studies comparing ex-CHM with other therapies for psoriasis vulgaris
| Author, year | Disease stage | Diagnostic criteria | Sample size E/C | Age E/C (years) | Duration E/C (years) | Intervention E/C | Treatment cycle (weeks) | follow-up (months) | Outcome measures |
|---|---|---|---|---|---|---|---|---|---|
| Cui et al, 2008 | Quiescent stage | China clinical dermatology | 62/57 | 45.82±13.89/ 38.72±12.17 | 160.92±147.24 /129.56±106.51 months | CHM bath+NB-UVB/ NB-UVB | 8 | NA | ①②⑤ |
| Zhang et al, 2009 | Quiescent stage | China clinical dermatology | 68/72 | 28.1±10.3/ 29.7±11.4 | 6.2±5.1 /5.8±4.8 | CHM fumigation+NB-UVB/ NB-UVB | 4 | NA | ①⑤ |
| Wu et al, 2010 | NA | Dermatology and venereology | 40/39 | 36.45±8.52/ 36.67±8.36 | 7.86±2.41 /8.06±2.65 | CHM bath+NB-UVB+/ NB-UVB | 12 | NA | ①②⑤ |
| Zhang and Wei, 2010 | Quiescent stage | China clinical dermatology | 30/30 | 36.5/34.6 | 10.37±9.59/ 10.85±10.46 | CHM bath+NB-UVB/ NB-UVB | 8 | NA | ①②⑤ |
| Shi et al, 2011 | Quiescent stage | Yang guoliang dermatology | 170/168 | 20-62/22-61 | 12.9/13.5 | CHM bath+NB-UVB/ NB-UVB | 8 | 6 | ①③⑤ |
| Wang et al, 2011 | NA | Modern Dermatology and venereology | 50/50 | 38.2/37.5 | 8.6/7.8 | CHM bath+NB-UVB+urea ointment/NB-UVB+urea ointment | 4 | NA | ①⑤ |
| Wu et al, 2011 | NA | Standards for diagnosis and curative effect of Chinese medical symptom | 75/65 | 32.5/34.8 | 18/20 months | CHM bath+NB-UVB+ex-hormone/ NB-UVB+ex-hormone | 6 | NA | ①②⑤ |
| Zhang et al, 2011 | NA | Guiding principles for clinical research of new Chinese medicine | 40/42 | 33.8±4.7/ 27.1±5.4 | 3.9±1.6/ 4.3±2.8 | CHM fumigation+NB-UVB/ NB-UVB | 4 | NA | ①②⑤ |
| Li et al, 2012 | NA | China clinical dermatology | 30/30 | 39.90±11.75/ 37.33±11.13 | 8.58±6.33/ 8.11±6.64 | CHM bath+NB-UVB+ex-hormone/ NB-UVB+ex-hormone | 4 | NA | ①②④⑤ |
| Luo et al, 2014 | Quiescent stage | China clinical dermatology | 56/52 | 31.52±6.23 | 3.5 months-13 years | CHM bath+NB-UVB/ NB-UVB | 4 | 6 | ①③⑤ |
| Su et al, 2015 | NA | China clinical dermatology | 42/43 | 38.25±8.33/ 42.57±11.79 | 13.57±6.85/ 15.89±7.23 | CHM bath+308nm excimer laser/ 308nm excimer laser | 8 | NA | ①②④⑤ |
| Wei and Jiang, 2015 | NA | China clinical dermatology | 64/64 | 14-75/17-68 | 1 month-25 years/ 6 months-20 years | CHM fumigation combined with external washing+acitretin/acitretin | 8 | NA | ①②⑤ |
| Zhang, 2015 | NA | Guiding principles for clinical research of new Chinese medicine | 29/29 | 44.21±11.97/ 41.97±10.46 | 9.62±9.01/ 7.52±6.08 | CHM ointment/tretinoin cream | 4 | NA | ①②⑤ |
| Chen, 2016 | NA | China clinical dermatology | 60/60 | 41.5/40.5 | 8.9/9.1 | CHM ointment+acitretin/acitretin | 12 | NA | ①⑤ |
| Fan, 2016 | NA | China clinical dermatology | 30/30 | 41.3±9.96/41.0±10.73 | 7.37±4.55/6.37±4.42 | CHM bath+NB-UVB/NB-UVB | 4 | NA | ①②④⑤ |
| Jiang, 2017 | Quiescent stage | China clinical dermatology | 30/30 | 43.23±10.70/ 42.43±11.29 | 1.85±0.89/ 1.78±0.81 | CHM external washing+calcipotriol ointment/calcipotriol ointment | 8 | NA | ①②⑤ |
| Song et al, 2017 | Quiescent stage | China clinical dermatology | 42/42 | 49.6±7.8/ 51.2±8.5 | 8.4±5.2/ 7.7±5.9 | CHM bath+NB-UVB+urea ointment/NB-UVB+urea ointment | 8 | NA | ①②④⑤ |
| Wang and Lu, 2019 | Quiescent stage | Clinical guidelines: venereal diseases | 46/41 | 41.59±10.83/ 42.24±9.66 | 6.20±2.72/ 6.46±2.53 | CHM external washing/ calcipotriol ointment | 6 | NA | ①②⑤ |
| Lin et al, 2020 | NA | Modern Dermatology | 40/40 | 39.43±9.35/ 42.47±9.08 | 32.55±5.98/ 32.56±5.72 months | CHM fumigation+calcipotriol ointment/calcipotriol ointment | 4 | NA | ①②⑤ |
Table 2 ex-CHM prescription compositions of included RCTs
| Study | Syndrome differentiation | ex-CHM compositions | ||
|---|---|---|---|---|
| Cui et al 2008 | NA | Wubeizi (Galla Chinensis), Huangbai (Cortex Phellodendri Amurensis), Danggui (Radix Angelicae Sinensis), Jianghuang (Rhizoma Curcumae Longae), Buguzhi (Fructus Psoraleae), etc. | ||
| Zhang et al 2009 | NA | Jinyinhua (Flos Lonicerae) 30 g, Tufuling (Rhizoma Smilacis Chinae) 30 g, Lianqiao (Fructus Forsythiae Suspensae) 30 g, stir-frying Huaihua (Flos Sophorae) 20 g, Ezhu (Rhizoma Curcumae Phaeocaulis) 15 g, Aiye (Folium Artemisiae Argyi) 20 g,Cebaiye (Cacumen Platycladi) 15 g, Taoren (Semen Persicae) 15 g, Danggui (Radix Angelicae Sinensis) 20 g, Dahuma (Centranthera Grandiflora) 20 g, Kushen (Radix Sophorae Flavescentis) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g. | ||
| Wu et al 2010 | Blood-heat syndrome | Shengdihuang (Radix Rehmanniae) 40 g, Jinyinhua (Flos Lonicerae) 30 g, Zihuadiding (Herba Violae Philippicae) 30 g, Pugongying (Herba Taraxaci Mongolici) 30 g, Wushaoshe (Zaocys) 15 g, Huangqin (Radix Scutellariae Baicalensis) 30 g, Zicao (Radix lithospermi) 30 g | ||
| Zhang et al 2010 | NA | Kushen (Radix Sophorae Flavescentis)100 g, Shechuangzi (Fructus Cnidii) 50 g, Shengdihuang (Radix Rehmanniae) 50 g, Yejuhua (Flos Dendranthematis Indici) 100 g, Ezhu (Rhizoma Curcumae Phaeocaulis) 50 g, Mangxiao (Nalrii Sulfas) 200 g, Tougucao (Herba Gaultheriae Grenulatae) 100 g, Aiye (Folium Artemisiae Argyi) 100 g. | ||
| Shi et al 2011 | NA | Tougucao (Herba Gaultheriae Grenulatae), Cebaiye (Cacumen Platycladi), Baixianpi (Cortex Dictamni Radicis), Danshen (Radix Salviae Miltiorrhizae), Danggui (Radix Angelicae Sinensis), Taoren (Semen Persicae), Kushen (Radix Sophorae Flavescentis), Difuzi (Fructus Kochiae Scopariae), Zhenzhufen (Margarita), etc. | ||
| Wang et al 2011 | NA | Huangqin (Radix Scutellariae Baicalensis), Baijiangcao (Herba Patriniae Scabiosaefoliae), Pugongying (Herba Taraxaci Mongolici), Chishao (Radix Paeoniae Rubra), Mudanpi (Cortex Moutan Radicis), Danshen (Radix Salviae Miltiorrhizae), Tiandong (Radix Asparagi Cochinchinensis), Shengdihuang (Radix Rehmanniae), Baixianpi (Cortex Dictamni Radicis), Difuzi (Fructus Kochiae Scopariae), Cangzhu (Rhizoma Atractylodis Lanceae). | ||
| Wu et al 2011 | Blood-dryness syndrome | Kushen (Radix Sophorae Flavescentis), Xuchangqing (Radix seu Herba Cynanchi Paniculati), Yejuhua (Flos Dendranthematis Indici), Zihuadiding (Herba Violae Philippicae), Jinyinhua (Flos Lonicerae), Shechuangzi (Fructus Cnidii), Gancao (Radix Glycyrrhizae). | ||
| Zhang et al 2011 | NA | Jinyinhua (Flos Lonicerae) 30 g, Tufuling (Rhizoma Smilacis Chinae) 30 g, Lianqiao (Fructus Forsythiae Suspensae)30 g, stir-frying Huaihua (Flos Sophorae) 20 g, Ezhu (Rhizoma Curcumae Phaeocaulis) 15 g, Aiye (Folium Artemisiae Argyi) 20 g, Cebaiye (Cacumen Platycladi) 15 g, Taoren (Semen Persicae) 15 g, Danggui (Radix Angelicae Sinensis) 20 g, Yamazi (Semen Lini Usitatissimi) 20 g, Kushen (Radix Sophorae Flavescentis) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g. | ||
| Li et al 2012 | blood-dryness syndrome | Danshen (Radix Salviae Miltiorrhizae), Danggui (Radix Angelicae Sinensis), Chishao (Radix Paeoniae Rubra), Difuzi (Fructus Kochiae Scopariae), Shechuangzi (Fructus Cnidii), Baixianpi (Cortex Dictamni Radicis), Kushen (Radix Sophorae Flavescentis) (all 30 g). | ||
| Luo et al 2014 | NA | Heshouwu (Radix Polygoni Multiflori) 10 g, Wumei (Fructus Mume) 30 g, Shengdihuang (Radix Rehmanniae) 20 g, Jixueteng (Caulis Spatholobi) 30 g, etc. | ||
| Su et al 2015 | NA | Shengdihuang (Radix Rehmanniae) 20 g, Tufuling (Rhizoma Smilacis Chinae) 20 g, Kushen (Radix Sophorae Flavescentis) 30 g, Tougucao (Herba Gaultheriae Grenulatae) 30 g, Baijiangcao (Herba Patriniae Scabiosaefoliae) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g, Difuzi (Fructus Kochiae Scopariae) 30 g. | ||
| Wei et al 2015 | NA | Huanglian (Rhizoma Coptidis) 12g, Diyu (Radix Sanguisorbae) 30 g, Difuzi (Fructus Kochiae Scopariae) 30 g, Qianliguang (Herba Senecionis Scandentis) 30 g, Kushen (Radix Sophorae Flavescentis) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g, Shechuangzi (Fructus Cnidii) 30 g, Huangbai (Cortex Phellodendri Amurensis)30 g, Xuchangqing (Radix seu Herba Cynanchi Paniculati) 30 g. | ||
| Zhang 2015 | Blood-heat syndrome | Qingdai (Indigo Naturalis), Baixianpi (Cortex Dictamni Radicis), Cebaiye (Cacumen Platycladi), Zicao (Radix lithospermi). | ||
| Chen 2016 | NA | Kushen (Radix Sophorae Flavescentis), Renshen (Radix Ginseng), Yinyanghuo (Herba Epimedii Brevicornus), Tiandong (Radix Asparagi Cochinchinensis), Tufuling (Rhizoma Smilacis Chinae), Heizhima (Semen Sesami Nigrum), Yuzhu (Rhizoma Polygonati odorati), Maidong (Radix Ophiopogonis Japonici), Bingpian (Borneolum Syntheticum). | ||
| Fan 2016 | NA | Huangbai (Cortex Phellodendri Amurensis) 20 g, Kushen (Radix Sophorae Flavescentis) 20 g, Difuzi (Fructus Kochiae Scopariae) 15 g, Diyu (Radix Sanguisorbae) 20 g, Shidagonglaogen (Radix Mahoniae Bealei) 60 g, Shiliupi (Pericarpium Punicae Granati)15 g, Qianliguang (Herba Senecionis Scandentis) 30 g, Huanglian (Rhizoma Coptidis)10 g. | ||
| Study | Syndrome differentiation | ex-CHM compositions | ||
| Jiang 2017 | blood-dryness syndrome | Huangjing (Rhizoma Polygonati Sibirici) 30 g, Shechuangzi (Fructus Cnidii) 30 g, Kuxingren (Semen Armeniacae Amarum) 20 g, Cebaiye (Cacumen Platycladi) 20 g, Difuzi (Fructus Kochiae Scopariae) 20 g, Qianliguang (Herba Senecionis Scandentis) 20 g, Gancao (Radix Glycyrrhizae) 6 g, Gualou (Fructus et Semen Trichosanthis) 10 g, Yemingsha (Faeces Vespertilionis)10 g, Kushen (Radix Sophorae Flavescentis) 12 g, Baihuasheshecao (Herba Hedyotdis) 10 g. | ||
| Song et al 2017 | NA | Cebaiye (Cacumen Platycladi), Kushen (Radix Sophorae Flavescentis), Yejuhua (Flos Dendranthematis Indici), Huajiao (Pericarpium Zanthoxyli Bungeani) (all 60 g). | ||
| Wang et al 2019 | blood-dryness syndrome | Cang’erzi (Fructus Xanthii), Shechuangzi (Fructus Cnidii), Fangfeng (Radix Saposhnikoviae), Kushen (Radix Sophorae Flavescentis), Baixianpi (Cortex Dictamni Radicis), Huangbai (Cortex Phellodendri Amurensis), Honghua (Flos Carthami), Difuzi (Fructus Kochiae Scopariae), Taoren (Semen Persicae). | ||
| Lin et al 2020 31 | blood-heat syndrome | Kushen (Radix Sophorae Flavescentis) 9 g, Zicao (Radix lithospermi) 15 g, Chaohuaimi (Sophora Flower Bud) 15 g, Meiguihua (Flos Rosae Rugosae) 10 g, Jixueteng (Caulis Spatholobi) 30 g, Shuiniujiao (Cornu Bubali) 30 g,Mudanpi (Cortex Moutan Radicis) 12 g, Baixianpi (Cortex Dictamni Radicis) 12 g, Cebaiye (Cacumen Platycladi) 20 g | ||
Table 2 ex-CHM prescription compositions of included RCTs
| Study | Syndrome differentiation | ex-CHM compositions | ||
|---|---|---|---|---|
| Cui et al 2008 | NA | Wubeizi (Galla Chinensis), Huangbai (Cortex Phellodendri Amurensis), Danggui (Radix Angelicae Sinensis), Jianghuang (Rhizoma Curcumae Longae), Buguzhi (Fructus Psoraleae), etc. | ||
| Zhang et al 2009 | NA | Jinyinhua (Flos Lonicerae) 30 g, Tufuling (Rhizoma Smilacis Chinae) 30 g, Lianqiao (Fructus Forsythiae Suspensae) 30 g, stir-frying Huaihua (Flos Sophorae) 20 g, Ezhu (Rhizoma Curcumae Phaeocaulis) 15 g, Aiye (Folium Artemisiae Argyi) 20 g,Cebaiye (Cacumen Platycladi) 15 g, Taoren (Semen Persicae) 15 g, Danggui (Radix Angelicae Sinensis) 20 g, Dahuma (Centranthera Grandiflora) 20 g, Kushen (Radix Sophorae Flavescentis) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g. | ||
| Wu et al 2010 | Blood-heat syndrome | Shengdihuang (Radix Rehmanniae) 40 g, Jinyinhua (Flos Lonicerae) 30 g, Zihuadiding (Herba Violae Philippicae) 30 g, Pugongying (Herba Taraxaci Mongolici) 30 g, Wushaoshe (Zaocys) 15 g, Huangqin (Radix Scutellariae Baicalensis) 30 g, Zicao (Radix lithospermi) 30 g | ||
| Zhang et al 2010 | NA | Kushen (Radix Sophorae Flavescentis)100 g, Shechuangzi (Fructus Cnidii) 50 g, Shengdihuang (Radix Rehmanniae) 50 g, Yejuhua (Flos Dendranthematis Indici) 100 g, Ezhu (Rhizoma Curcumae Phaeocaulis) 50 g, Mangxiao (Nalrii Sulfas) 200 g, Tougucao (Herba Gaultheriae Grenulatae) 100 g, Aiye (Folium Artemisiae Argyi) 100 g. | ||
| Shi et al 2011 | NA | Tougucao (Herba Gaultheriae Grenulatae), Cebaiye (Cacumen Platycladi), Baixianpi (Cortex Dictamni Radicis), Danshen (Radix Salviae Miltiorrhizae), Danggui (Radix Angelicae Sinensis), Taoren (Semen Persicae), Kushen (Radix Sophorae Flavescentis), Difuzi (Fructus Kochiae Scopariae), Zhenzhufen (Margarita), etc. | ||
| Wang et al 2011 | NA | Huangqin (Radix Scutellariae Baicalensis), Baijiangcao (Herba Patriniae Scabiosaefoliae), Pugongying (Herba Taraxaci Mongolici), Chishao (Radix Paeoniae Rubra), Mudanpi (Cortex Moutan Radicis), Danshen (Radix Salviae Miltiorrhizae), Tiandong (Radix Asparagi Cochinchinensis), Shengdihuang (Radix Rehmanniae), Baixianpi (Cortex Dictamni Radicis), Difuzi (Fructus Kochiae Scopariae), Cangzhu (Rhizoma Atractylodis Lanceae). | ||
| Wu et al 2011 | Blood-dryness syndrome | Kushen (Radix Sophorae Flavescentis), Xuchangqing (Radix seu Herba Cynanchi Paniculati), Yejuhua (Flos Dendranthematis Indici), Zihuadiding (Herba Violae Philippicae), Jinyinhua (Flos Lonicerae), Shechuangzi (Fructus Cnidii), Gancao (Radix Glycyrrhizae). | ||
| Zhang et al 2011 | NA | Jinyinhua (Flos Lonicerae) 30 g, Tufuling (Rhizoma Smilacis Chinae) 30 g, Lianqiao (Fructus Forsythiae Suspensae)30 g, stir-frying Huaihua (Flos Sophorae) 20 g, Ezhu (Rhizoma Curcumae Phaeocaulis) 15 g, Aiye (Folium Artemisiae Argyi) 20 g, Cebaiye (Cacumen Platycladi) 15 g, Taoren (Semen Persicae) 15 g, Danggui (Radix Angelicae Sinensis) 20 g, Yamazi (Semen Lini Usitatissimi) 20 g, Kushen (Radix Sophorae Flavescentis) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g. | ||
| Li et al 2012 | blood-dryness syndrome | Danshen (Radix Salviae Miltiorrhizae), Danggui (Radix Angelicae Sinensis), Chishao (Radix Paeoniae Rubra), Difuzi (Fructus Kochiae Scopariae), Shechuangzi (Fructus Cnidii), Baixianpi (Cortex Dictamni Radicis), Kushen (Radix Sophorae Flavescentis) (all 30 g). | ||
| Luo et al 2014 | NA | Heshouwu (Radix Polygoni Multiflori) 10 g, Wumei (Fructus Mume) 30 g, Shengdihuang (Radix Rehmanniae) 20 g, Jixueteng (Caulis Spatholobi) 30 g, etc. | ||
| Su et al 2015 | NA | Shengdihuang (Radix Rehmanniae) 20 g, Tufuling (Rhizoma Smilacis Chinae) 20 g, Kushen (Radix Sophorae Flavescentis) 30 g, Tougucao (Herba Gaultheriae Grenulatae) 30 g, Baijiangcao (Herba Patriniae Scabiosaefoliae) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g, Difuzi (Fructus Kochiae Scopariae) 30 g. | ||
| Wei et al 2015 | NA | Huanglian (Rhizoma Coptidis) 12g, Diyu (Radix Sanguisorbae) 30 g, Difuzi (Fructus Kochiae Scopariae) 30 g, Qianliguang (Herba Senecionis Scandentis) 30 g, Kushen (Radix Sophorae Flavescentis) 30 g, Baixianpi (Cortex Dictamni Radicis) 30 g, Shechuangzi (Fructus Cnidii) 30 g, Huangbai (Cortex Phellodendri Amurensis)30 g, Xuchangqing (Radix seu Herba Cynanchi Paniculati) 30 g. | ||
| Zhang 2015 | Blood-heat syndrome | Qingdai (Indigo Naturalis), Baixianpi (Cortex Dictamni Radicis), Cebaiye (Cacumen Platycladi), Zicao (Radix lithospermi). | ||
| Chen 2016 | NA | Kushen (Radix Sophorae Flavescentis), Renshen (Radix Ginseng), Yinyanghuo (Herba Epimedii Brevicornus), Tiandong (Radix Asparagi Cochinchinensis), Tufuling (Rhizoma Smilacis Chinae), Heizhima (Semen Sesami Nigrum), Yuzhu (Rhizoma Polygonati odorati), Maidong (Radix Ophiopogonis Japonici), Bingpian (Borneolum Syntheticum). | ||
| Fan 2016 | NA | Huangbai (Cortex Phellodendri Amurensis) 20 g, Kushen (Radix Sophorae Flavescentis) 20 g, Difuzi (Fructus Kochiae Scopariae) 15 g, Diyu (Radix Sanguisorbae) 20 g, Shidagonglaogen (Radix Mahoniae Bealei) 60 g, Shiliupi (Pericarpium Punicae Granati)15 g, Qianliguang (Herba Senecionis Scandentis) 30 g, Huanglian (Rhizoma Coptidis)10 g. | ||
| Study | Syndrome differentiation | ex-CHM compositions | ||
| Jiang 2017 | blood-dryness syndrome | Huangjing (Rhizoma Polygonati Sibirici) 30 g, Shechuangzi (Fructus Cnidii) 30 g, Kuxingren (Semen Armeniacae Amarum) 20 g, Cebaiye (Cacumen Platycladi) 20 g, Difuzi (Fructus Kochiae Scopariae) 20 g, Qianliguang (Herba Senecionis Scandentis) 20 g, Gancao (Radix Glycyrrhizae) 6 g, Gualou (Fructus et Semen Trichosanthis) 10 g, Yemingsha (Faeces Vespertilionis)10 g, Kushen (Radix Sophorae Flavescentis) 12 g, Baihuasheshecao (Herba Hedyotdis) 10 g. | ||
| Song et al 2017 | NA | Cebaiye (Cacumen Platycladi), Kushen (Radix Sophorae Flavescentis), Yejuhua (Flos Dendranthematis Indici), Huajiao (Pericarpium Zanthoxyli Bungeani) (all 60 g). | ||
| Wang et al 2019 | blood-dryness syndrome | Cang’erzi (Fructus Xanthii), Shechuangzi (Fructus Cnidii), Fangfeng (Radix Saposhnikoviae), Kushen (Radix Sophorae Flavescentis), Baixianpi (Cortex Dictamni Radicis), Huangbai (Cortex Phellodendri Amurensis), Honghua (Flos Carthami), Difuzi (Fructus Kochiae Scopariae), Taoren (Semen Persicae). | ||
| Lin et al 2020 31 | blood-heat syndrome | Kushen (Radix Sophorae Flavescentis) 9 g, Zicao (Radix lithospermi) 15 g, Chaohuaimi (Sophora Flower Bud) 15 g, Meiguihua (Flos Rosae Rugosae) 10 g, Jixueteng (Caulis Spatholobi) 30 g, Shuiniujiao (Cornu Bubali) 30 g,Mudanpi (Cortex Moutan Radicis) 12 g, Baixianpi (Cortex Dictamni Radicis) 12 g, Cebaiye (Cacumen Platycladi) 20 g | ||
Table 3 Meta-analysis of the response rate, PASI, adverse dermatological reactions (comparing ex-CHM with other therapies for psoriasis vulgaris treatment)
 |
Table 3 Meta-analysis of the response rate, PASI, adverse dermatological reactions (comparing ex-CHM with other therapies for psoriasis vulgaris treatment)
| |
Figure 3 Funnel plot of the response rate
Figure 3 Funnel plot of the response rate
Table 4 Descriptive analysis of the response rate, PASI, adverse reactions (comparing ex-CHM with other therapies for psoriasis vulgaris treatment)
| Study | Sample size (E/C) | Intervention (E/C) | Response rate | PASI | Adverse dermatological reactions | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | P value | MD (95% CI) | P value | RR (95% CI) | P value | ||||||||||||
| Zhang 2015 | 29/29 | CHM ointment/tretinoin cream | 1.40 (0.50, 3.90) | 0.52 | –0.23 (–1.34, 0.88) | 0.69 | 0.20 (0.01, 3.99) | 0.29 | |||||||||
| Chen 2016 | 60/60 | CHM ointment+acitretin /acitretin | 1.02 (0.88, 1.18) | 0.79 | 0.28 (0.13, 0.60) | 0.001 | |||||||||||
| Wang et al 2019 | 46/41 | CHM external washing/calcipotriol ointment | 1.01 (0.79, 1.28) | 0.96 | –0.14 (–1.32, 1.04) | 0.82 | 0.13 (0.01, 2.40) | 0.17 | |||||||||
| Jiang 2017 | 30/30 | CHM external washing+ exhormone /ex-hormone | 1.39 (1.00, 1.94) | 0.05 | –2.00 (–2.93, –1.07) | <0.0001 | 0.20 (0.01, 4.00) | 0.29 | |||||||||
| Wei et al 2015 | 64/64 | CHM fumigation combined with external washing+ acitretin/acitretin | 1.26 (1.02, 1.56) | 0.03 | –2.95 (–4.25, –1.65) | <0.000 01 | 2.00 (0.38, 10.54) | 0.41 | |||||||||
| Lin et al 2020 | 40/40 | CHM fumigation+calcipotriol ointment /calci-potriol ointment | 5.00 (2.13, 1.75) | 0.0002 | –2.88 (–3.13, –2.63) | <0.000 01 | 0.20 (0.05, 0.86) | 0.03 | |||||||||
| Su et al 2015 | 42/43 | CHM bath+308 nm excimer laser/308 nm excimer laser | 1.18 (0.96, 1.46) | 0.11 | –4.28 (–6.12, –2.44) | <0.000 01 | 0.26 (0.08, 0.84) | 0.02 | |||||||||
Table 4 Descriptive analysis of the response rate, PASI, adverse reactions (comparing ex-CHM with other therapies for psoriasis vulgaris treatment)
| Study | Sample size (E/C) | Intervention (E/C) | Response rate | PASI | Adverse dermatological reactions | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | P value | MD (95% CI) | P value | RR (95% CI) | P value | ||||||||||||
| Zhang 2015 | 29/29 | CHM ointment/tretinoin cream | 1.40 (0.50, 3.90) | 0.52 | –0.23 (–1.34, 0.88) | 0.69 | 0.20 (0.01, 3.99) | 0.29 | |||||||||
| Chen 2016 | 60/60 | CHM ointment+acitretin /acitretin | 1.02 (0.88, 1.18) | 0.79 | 0.28 (0.13, 0.60) | 0.001 | |||||||||||
| Wang et al 2019 | 46/41 | CHM external washing/calcipotriol ointment | 1.01 (0.79, 1.28) | 0.96 | –0.14 (–1.32, 1.04) | 0.82 | 0.13 (0.01, 2.40) | 0.17 | |||||||||
| Jiang 2017 | 30/30 | CHM external washing+ exhormone /ex-hormone | 1.39 (1.00, 1.94) | 0.05 | –2.00 (–2.93, –1.07) | <0.0001 | 0.20 (0.01, 4.00) | 0.29 | |||||||||
| Wei et al 2015 | 64/64 | CHM fumigation combined with external washing+ acitretin/acitretin | 1.26 (1.02, 1.56) | 0.03 | –2.95 (–4.25, –1.65) | <0.000 01 | 2.00 (0.38, 10.54) | 0.41 | |||||||||
| Lin et al 2020 | 40/40 | CHM fumigation+calcipotriol ointment /calci-potriol ointment | 5.00 (2.13, 1.75) | 0.0002 | –2.88 (–3.13, –2.63) | <0.000 01 | 0.20 (0.05, 0.86) | 0.03 | |||||||||
| Su et al 2015 | 42/43 | CHM bath+308 nm excimer laser/308 nm excimer laser | 1.18 (0.96, 1.46) | 0.11 | –4.28 (–6.12, –2.44) | <0.000 01 | 0.26 (0.08, 0.84) | 0.02 | |||||||||
Table 5 Descriptive analysis of DLQI (comparing ex-CHM with other therapies for psoriasis vulgaris treatment)
| Study | Sample size (E/C) | Intervention (E/C) | MD (95%CI) | P value |
|---|---|---|---|---|
| Su et al 2015 | 42/43 | CHM bath+308nm excimer laser/308 nm excimer laser | –2.67 (–4.91, –0.43) (–4.91, –0.43) | 0.02 |
| excimer laser | ||||
| Fan 2016 | 30/30 | CHM bath+NB-UVB/NB-UVB | –1.56 (–2.66, –0.46) (–2.66, –0.46) | 0.005 |
| Song et al 2017 | 42/42 | CHM bath+NB-UVB+urea ointment /NB-UVB+urea ointment | –5.29 (–7.20, –3.38) | <0.00001 |
| Li et al 2012 | 30/30 | CHM bath+NB-UVB+ex-hormone /NB-UVB+ex-hormone | –3.63 (–5.93, –1.33) | 0.002 |
Table 5 Descriptive analysis of DLQI (comparing ex-CHM with other therapies for psoriasis vulgaris treatment)
| Study | Sample size (E/C) | Intervention (E/C) | MD (95%CI) | P value |
|---|---|---|---|---|
| Su et al 2015 | 42/43 | CHM bath+308nm excimer laser/308 nm excimer laser | –2.67 (–4.91, –0.43) (–4.91, –0.43) | 0.02 |
| excimer laser | ||||
| Fan 2016 | 30/30 | CHM bath+NB-UVB/NB-UVB | –1.56 (–2.66, –0.46) (–2.66, –0.46) | 0.005 |
| Song et al 2017 | 42/42 | CHM bath+NB-UVB+urea ointment /NB-UVB+urea ointment | –5.29 (–7.20, –3.38) | <0.00001 |
| Li et al 2012 | 30/30 | CHM bath+NB-UVB+ex-hormone /NB-UVB+ex-hormone | –3.63 (–5.93, –1.33) | 0.002 |
| 1 |
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
DOI PMID |
| 2 | Griffiths CEM, Walt JM, Ashcroft DM, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol 2017; 177: e4-7. |
| 3 | Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989; 146: 69-71. |
| 4 | Ayala F. Clinical presentation of psoriasis. Reumatismo 2007; 59: 40-5. |
| 5 | Bruner CR, Feldman SR, Ventrapragada M, Fleischer Jr AB. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9: 2-12. |
| 6 | Yang DQ, Zhang LX, Bai YP. Clinical observation of sequential therapy of calcipotriol ointment and halometasone cream in the treatment of plaque psoriasis. Lin Chuang Pi Fu Bing Xue Za Zhi 2009; 38: 401-3. |
| 7 | Ma WP, Liu J, Zhu HP. Conversion of psoriasis vulgaris to erythrodermic psoriasis caused by glucocorticoid: a case report. Pi Fu Bing Yu Xing Bing 2010; 32: 63. |
| 8 | Psoriasis Professional Committee of Dermatology Branch of Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of psoriasis (2018 full edition). Zhong Hua Pi Fu Ke Za Zhi 2019; 52: 667-710. |
| 9 | Cheng YY, Lu YP. Clinical application of Sanzi granule. Zhong Yi Wai Ke Za Zhi 2014; 23: 63-4. |
| 10 |
Man MQ, Shi Y, Man M, et al. Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and antiinflammatory activity in murine disease models. Exp Dermatol 2008; 17: 681-7.
DOI URL |
| 11 |
Li N, Li YQ, Li HY, Guo W, Bai YP. Efficacy of externally applied Chinese herbal drugs in treating psoriasis: a systematic review. Chin J Integr Med 2012; 18: 222-9.
DOI URL |
| 12 | Zheng XY. Guiding principles for clinical research of new Chinese medicine. Beijing: China Medical Science and Technology Press, 2002: 299-302. |
| 13 | Cui BN, Sun YX, Liu WL, Liao GL. Efficacy observation of narrow-spectrum uvb combined with Yuyin prescript tion bath in the treatment of psoriasis vulgaris. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2008; 355-7. |
| 14 | Zhang CM, Wei G, Zhang CH, Pang L, Shi YJ, Cai Y. The efficacy of Chinese herbal medicine fumigation combined with ultraviolet irradiation in the treatment of psoriasis and their efficacy on Thl/Th2 cytokines in serum. Zhong Hua Wu Li Yi Xue Yu Kang Fu Za Zhi 2009; 491-2. |
| 15 | Wu LN, Huang LN, Xue RZ. Efficacy observation and nursing care of narrow-spectrum uvb combined with Chinese herbal medicine bath in the treatment of psoriasis vulgaris. Pi Fu Xing Bing Zhen Liao Xue Za Zhi 2010; 17: 242-4. |
| 16 | Zhang YS, Wei LP. Efficacy observation of NB-UVB combined with Chinese herbal medicine in the treatment of psoriasis vulgaris. Zhong Guo Ma Feng Pi Fu Bing Za Zhi 2010; 26: 815. |
| 17 | Shi XL, Pan YM, Ma HY, Yang XF. Clinical efficacy observation of NB-UVB combined with Chinese herbal medicine bath in the treatment of psoriasis vulgaris. Zhong Guo Ji Guang Yi Xue Za Zhi 2011; 20: 314-7. |
| 18 | Wang ZX, Wang HJ, Yu ZH, et al. Efficacy observation of Chinese herbal medicine bath combined with NB-UVB in the treatment of psoriasis vulgaris. Henan Da Xue Xue Bao (Medical Science) 2011; 30: 226-7. |
| 19 | Wu B, Chen XD, Xia D, et al. Efficacy observation of Chinese herbal medicine bath combined with NB-UVB in the treatment of psoriasis vulgaris. Zhong Guo Zhong Xi Yi Jie He Pi Fu Xing Bing Xue Za Zhi 2011; 10: 304-5. |
| 20 | Zhang CH, Zhang CM, Du XX, Cai Y. Efficacy observation of Chinese herbal medicine fumigation combined with ultraviolet radiation in the treatment of psoriasis vulgaris. Zhong Hua Wu Li Yi Xue Yu Kang Fu Za Zhi 2011; 33: 937-9. |
| 21 | Li J, Sun SM, Yang ZB. Efficacy of Traditional Chinese Medicine bath combined with narrow spectrum uvb in the treatment of psoriasis vulgaris and the analysis of quality of life. Zhong Guo Zhong Xi Yi Jie He Pi Fu Xing Bing Xue Za Zhi 2012; 11: 161-2. |
| 22 | Luo GP, Qu YB, DI DK, et al. Clinical observation of traditional Chinese medicine bath combined with narrow-spectrum uvb in the treatment of psoriasis. Hubei Zhong Yi Za Zhi 2014; 36: 12-3. |
| 23 | Su LN, Yi XM, Ding YF, Yu N, Ma J. Clinical observation and quality of life evaluation of 42 patients with plaque psoriasis treated with Traditional Chinese Medicine bath combined with 308nm excimer laser. Zhong Guo Pi Fu Xing Bing Xue Za Zhi 2015; 29: 967-9. |
| 24 | Wei B, Jiang ZL. Clinical observation of acitretin combined with Shufu powder fumigation and washing in the treatment of psoriasis vulgaris. Zhong Guo Zhong Xi Yi Jie He Pi Fu Xing Bing Xue Za Zhi 2015; 14: 45-7. |
| 25 | Zhang YL. Clinical efficacy observation of proposed Xiaobi ointment in the treatment of psoriasis blood-heat syndrome. Beijing: Beijing University of Chinese Medicine, 2015: 29-40. |
| 26 | Chen L. Clinical efficacy observation of Fushu Zhiyang ointment combined with acitretin in the treatment of psoriasis vulgaris. Zhong Guo Bao Jian Ying Yang 2016; 26: 84-5. |
| 27 | Fan JJ. Clinical efficacy study of Shufu powder combined with narrow-band uvb in the treatment of psoriasis vulgaris. Guangxi: Guangxi University of Traditional Chinese Medicine, 2016: 17-27. |
| 28 | Jiang NL. Clinical study of Runfu Zhiyang lotion in the treatment of psoriasis vulgaris (deficiency of blood and dryness of wind syndrome). Hunan: Hunan University of Traditional Chinese Medicine, 2017: 3-14. |
| 29 | Song X, Tang SW, Jiang WC, Yang Y, Wang QL, Xie SQ. Traditional Chinese Medicine bath combined with NB-UVB irradiation in the treatment of stable psoriasis vulgaris and their effect on patients' quality of life. Zhong Guo Pi Fu Xing Bing Xue Za Zhi 2017; 31: 757-9+783. |
| 30 | Wang JQ, Lu YP. Clinical observation of Niupixuan lotion in the treatment of psoriasis vulgaris of deficiency of blood and dryness of wind syndrome. Shanxi Zhong Yi 2019; 35: 40-1+46. |
| 31 | Lin J, Fang YM, Ma LL, Ji C, Li YY. Clinical study on the treatment of psoriasis with traditional Chinese medicine steam therapy combined with Calcipotriol Ointment. Xin Zhong Yi 2020; 52: 94-7. |
| 32 |
Fragoulis GE, Siebert S, Mclnnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune mediated diseases. Annu Rev Med 2016; 67: 337-53.
DOI PMID |
| 33 |
Luan L, Han S, Wang H, Liu X. Down-regulation of the Th1, Th17and Th22 pathways due to anti-TNF-α treatment in psoriasis. Int Immunopharmacol 2015; 29: 278-84.
DOI PMID |
| 34 |
Kollipara R, Downing C, Gordon R, Tyring S. Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett 2015; 20: 1-4.
PMID |
| 35 |
Chen X, Zhang RT, Duan XW, Xue M, Qu TG, Li LL. Effectiveness of Xiaoyin Jiedu granules in the treatment of psoriasis vulgaris in patients with blood-heat symptom patterns in terms of Traditional Chinese Medicine. J Tradit Chin Med 2020; 40: 863-9.
DOI PMID |
| 36 | Wang JP, Zhang HY, Fu XC. Study advances of chemical constituents and pharmacological effects of Rhizom a Smilacis Glabrae. Hai Xia Yao Xue 2013; 25: 42-4. |
| 37 |
Deng S, May BH, Zhang AL, Lu C, Xue CC. Topicl herbal formulae in the management of psoriasis: systematic review with Meta-analysis of clinical studies and investigation of the pharmacological action of main herbs. Phytother Res Ptr 2014; 28: 480-97.
DOI URL |
| 38 | Xie XR, Zhang L, Liu X, Lin Y, Zhang L, Li P. Effect of shikonin on the proliferation of keratinocytes and expression of chemo kine induced by IL-17. Zhong Guo Zhong Yao Za Zhi 2015; 40: 946-9. |
| 39 | Zhou Y, Mou KH, Han D, et al. Matrine can inhibit the expression of keratinocytes IL17RA, IL21R and IL 22 R1 induced by Th17. Xian Jiao Tong Da Xue Xue Bao (Medical Sciences) 2014; 35: 695-9. |
| 40 | Shi HJ, Zhou R, Jin SJ, Yang J, Zhang XM. Effects of oxymatrine on levels of IL-2, IL-10 and TNF-α in serum of mouse models with psoriasis. Hua Xi Yao Xue Za Zhi 2010; 25: 418-20. |
| 41 | Yu JJ. Systematic evaluation of the efficacy of external application therapies of Chinese medicine in the treatment of psoriasis vulgaris. Guangzhou: Guangzhou University of Chinese Medicine, 2013: 29-31. |
| [1] | QIN Xiaoyu, WANG Chunai, XUE Jianjun, ZHANG Jie, LU Xiaoting, DING Shengshuang, GE Long, WANG Minzhen. Efficacy of electroacupuncture on myocardial protection and postoperative rehabilitation in patients undergoing cardiac surgery with cardiopulmonary bypass: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 1-15. |
| [2] | DAI Xiaoling, ZHANG Anming, LIN Hui, SHI Bei, REN Yi, WEN Hongzhu, FEI Xiaoyan, LIN Jiang. Qingchang suppositry (清肠栓) induced remission in patients with mild-to-moderate ulcerative proctitis: a multicenter, prospective, randomized, parallel-controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 156-162. |
| [3] | LIU Tingting, LIU Tongou, LIU Mingfu. Effectiveness and safety of acupuncture in treatment of pregnancy-related symptoms: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 16-26. |
| [4] | WANG Yichen, WU Shiyi, WANG Zhengyan, CHANG Wenling, XIE Zhihao, TANG Xing, ZHAO Songmei, ZHOU Jing, CHEN Zehong, WANG Chao, YANG Chunxia. Efficacy of Zhumian Tang formula granules (助眠汤配方颗粒) combined with eszopiclone for the treatment of poor sleep quality: a multi-center, randomized controlled, superiority trial [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 163-171. |
| [5] | YANG Yi, YE Huijun, ZHENG Huiling, JIN Lihua. Clinical observation on 90 cases of primary dysmenorrhea treated by buccal acupuncture therapy: a randomized controlled study [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 172-181. |
| [6] | WANG Jiabao, ZHANG Lishuang, NIU Baihan, YU Yajun, YANG Fengwen, MIAO Lin, CHAI Lijuan, DING Xinya, SUN Yingjie, WANG Yujing, WANG Lin, ZHANG Han, WANG Yi, LI Lin. Efficacy and safety of Weichang’ an pill (胃肠安丸) combined with Western Medicine on gastrointestinal diseases: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1057-1067. |
| [7] | FAN Rong, HE Haoyu, TANG Tao, CUI Hanjin. Long-term effects of Qingfei Paidu decoction (清肺排毒汤) in patients with coronavirus disease 2019 acute pneumonia after treatment: a protocol for systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1068-1071. |
| [8] | DAI Zeqi, LIAO Xing, GUAN Yueyue, ZENG Zixiu, TANG Jun, HU Jing. Bloodletting puncture in the treatment of acute ischemic stroke: protocol for a mixed-method study of a multi-center randomized controlled trial and focus group [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1259-1267. |
| [9] | XU Yani, ZHANG Yutong, HE Weile, DAI Linglin, TANG Ding, WANG Jialing, ZHANG Xufen, CHEN Qin, CHEN Lifang, WANG Zhanglian, ZHAN Mingjie. Efficiency and safety of acupuncture for women with premature ovarian insufficiency: study protocol for a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1268-1274. |
| [10] | XU Xiangru, ZHOU Yi, CHEN Gang, LEI Ming, ZHANG Wen, WU Xinxin, PU Yuting, CHEN Caiyu, SUN Yuting, ZHOU Shuang, FANG Bangjiang. Clinical efficacy of Buzhong Yiqi decoction (补中益气汤) in the treatment of hospital-acquired pneumonia with multi-drug resistant bacteria: a prospective, randomized, multicenter controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1010-1018. |
| [11] | ZHAO Ming, LUO Yimiao, WANG Huichan, CAO Yu, MA Lina, PEI Hui, LI Hao. Guilingji capsule (龟龄集胶囊) for Alzheimer's disease: secondary analysis of a randomized non-inferiority controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1019-1025. |
| [12] | ZHANG Meizhen, HAO Xiaohui, TANG Yiting, CHEN Yupeng, HE Puyu, ZHAO Liming, PANG Bing, NI Qing. Efficacy and safety of Buyang Huanwu decoction (补阳还五汤) for diabetic peripheral neuropathy: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 841-850. |
| [13] | YANG Yuqing, CHEN Yuhuan, LI Chunxiao, LING Xiao, WANG Panpan, GUO Jing, ZHANG Yingying. Effectiveness and safety of Pingxiao capsule (平消胶囊) as adjuvant therapy in treatment of breast cancer: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 851-859. |
| [14] | ZHAO HuiYan, JUN Purumea, LEE Chaewon, HAN Chang-Hyun. Acupoint catgut embedding for simple obesity in animal studies: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 860-867. |
| [15] | SUN Wu, ZHAO Yuwei, LIAO Liang, ZHAO Zhonghui, CHEN Shiqi, YAN Xiaoling, WANG Xueyao, CHAO Guojun, ZHOU Jian. Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 631-639. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
